Business Context and Reporting Period
Company: enVVeno Medical Corporation (NVNO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: enVVeno is a medical device company developing bioprosthetic solutions for Chronic Venous Insufficiency (CVI). The company previously pursued the surgical VenoValve but received a "not-approvable" letter from the FDA in August 2025. It has since pivoted to focus exclusively on the enVVe System, a next-generation, non-surgical, transcatheter replacement venous valve. Pre-clinical testing for enVVe is complete, and discussions regarding a pivotal trial expected to begin in 2026 are underway.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(19.5) million | $(21.8) million |
| Operating Expenses | $20.9 million | $23.8 million |
| Research & Development | $10.0 million | $12.2 million |
| Selling, General & Admin | $10.9 million | $11.6 million |
| Cash & Cash Equivalents | $3.1 million | $1.8 million |
| Short-Term Investments | $25.1 million | $41.4 million |
| Total Cash & Investments | $28.2 million | $43.1 million |
| Working Capital | $26.7 million | $41.6 million |
| Debt | None | None |
Note: All share and per-share data has been retroactively adjusted for a 1-for-35 reverse stock split effective January 20, 2026.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $2.3 million (11%) to $19.5 million, driven primarily by a $2.9 million reduction in operating expenses.
- R&D Expense Decline: R&D expenses dropped 19% to $10.0 million, largely due to $2.4 million in lower costs associated with the VenoValve study as participant follow-up decreased.
- SG&A Expense Decline: SG&A expenses decreased 6% to $10.9 million, attributed to $1.1 million in non-recurring legal costs incurred in 2024 and lower stock-based compensation, partially offset by severance costs in 2025.
- Investment Portfolio: Short-term investments decreased by $16.3 million to $25.1 million as the company held fewer U.S. Treasury securities in 2025 compared to 2024.
- Regulatory Status: The company received a final unfavorable decision on its appeal regarding the VenoValve PMA application in November 2025, confirming the product will not be approved in its current form.
Guidance, Outlook, and Risks
- Strategic Pivot: The company has abandoned commercialization efforts for the surgical VenoValve outside the U.S. and is focusing all resources on the non-surgical enVVe System.
- Cash Burn & Runway: Management anticipates a cash burn rate of approximately $4 million to $5 million per quarter in 2026. Based on year-end 2025 liquidity ($28.2 million), the company expects sufficient capital to fund operations through mid-2027.
- Capital Needs: The company will require additional capital in the future to complete clinical trials and commercialize products. Failure to raise funds could threaten its viability as a going concern.
- Regulatory Risks: There is no assurance the enVVe System will receive FDA approval. The recent rejection of the VenoValve highlights the high regulatory bar for venous valve replacements, specifically regarding safety and efficacy data.
- Supply Chain: The company relies on only two domestic vendors for porcine tissue, creating a supply concentration risk.
Investor Verification Checklist
- Regulatory Pathway: Verify the specific endpoints and trial design agreed upon with the FDA for the enVVe pivotal trial expected to start in 2026.
- Liquidity Runway: Monitor quarterly cash burn rates to confirm the "mid-2027" runway projection remains valid given the anticipated increase in expenses.
- Reverse Stock Split Impact: Confirm the impact of the 1-for-35 reverse stock split on trading liquidity and Nasdaq listing compliance (noted as regained compliance in Feb 2026).
- Supply Chain Resilience: Assess the contingency plans for the two sole-source suppliers of porcine tissue.
- Equity Dilution: Review upcoming financing plans, as the company has no revenue and will likely need to issue equity or debt, potentially diluting existing shareholders.